Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C1 | P04150 | 7/20 | 1.00 |
| ▸ | PGR | P06401 | 4/20 | 0.78 |
| ▸ | HIF1A | Q16665 | 4/20 | 0.78 |
| ▸ | HRH1 | P35367 | 1/20 | 0.78 |
| ▸ | SERPINA6 | P08185 | 3/20 | 0.76 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.73 |
| ▸ | AR | P10275 | 3/20 | 0.73 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.68 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.68 |
| ▸ | FNTA | P49354 | 1/20 | 0.68 |
| ▸ | FNTB | P49356 | 1/20 | 0.68 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | CYP2C19 | P33261 | 3/20 | 0.61 |
| ▸ | CYP3A4 | P08684 | 4/20 | 0.58 |
| ▸ | SHBG | P04278 | 2/20 | 0.58 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.58 |
| ▸ | NR3C2 | P08235 | 1/20 | 0.58 |
| ▸ | MAPT | P10636 | 1/20 | 0.58 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.58 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.58 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Fludrocortisone SCHEMBL5188889 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL4545 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL19327146 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL4323075 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL10598529 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL23975175 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL14373312 | 1.00 | NR3C1 (1.00) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| Fludrocortisone SCHEMBL21297043 | 0.98 | NR3C1 (0.96) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| SCHEMBL8735123 | 0.93 | NR3C1 (0.87) | NR3C1PGRHIF1AHRH1SERPINA6 | |
| SCHEMBL8735124 | 0.93 | NR3C1 (0.87) | NR3C1PGRHIF1AHRH1SERPINA6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4079311-B1 | NMN AND DERIVATIVES FOR USE IN THE TREATMENT OF DEPRESSION AND/OR ANXIETY IN PATIENTS HAVING A FORM OF PARKINSONISM | NUVAMID SA (CH) | 2025-10-01 | — | — | EP | claimed |
| EP-2796112-B2 | Degradable implantable medical devices | ELIXIR MEDICAL CORP (US) | 2023-08-09 | — | — | EP | claimed |
| WO-2018050938-A1 | PRE-LOADED INJECTABLE DEVICE FOR TREATING CEREBRAL EDEMA | SERVICIO ANDALUZ DE SALUD (ES) | 2018-03-22 | — | — | WO | claimed |
| CN-1320880-C | Improved formulation for topical non-invasive application in vivo | IDEA INNOVAT DERMALE APPL GMBH (DE) | 2007-06-13 | — | — | CN | claimed |
| CN-1327382-A | Improved formulation for topical non-invasive application in vivo | IDEA INNOVAT DERMALE APPL GMBH (DE) | 2001-12-19 | — | — | CN | claimed |
| EP-3350313-B1 | DERIVATION OF LIVER ORGANOIDS FROM HUMAN PLURIPOTENT STEM CELLS | AGENCY FOR SCIENCE TECH AND RESEARCH ASTARSTAR (SG) | 2025-11-26 | — | — | EP | disclosed |
| WO-2018050938-A1 | PRE-LOADED INJECTABLE DEVICE FOR TREATING CEREBRAL EDEMA | SERVICIO ANDALUZ DE SALUD (ES) | 2018-03-22 | — | — | WO | disclosed |
| EP-3238781-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID ACCUMULATION IN AND/ OR UNDER THE RETINA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2017-11-01 | — | — | EP | disclosed |
| US-9610294-B2 | Methods and compositions for the treatment of fluid accumulation in and/or under the retina | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2017-04-04 | — | — | US | disclosed |
| US-20170027860-A1 | METHODS AND PHARMACEUTICAL COMPOSITIONS FOR THE TREATMENT OF OCULAR INFLAMMATORY DISEASES | INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE (INSERM) (FR) | 2017-02-02 | — | — | US | disclosed |
| EP-2977084-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID ACCUMULATION IN AND/ OR UNDER THE RETINA | INSERM (Institut National de la Santé et de la Recherche Médicale) (FR) | 2016-01-27 | — | — | EP | disclosed |
| EP-2568986-B1 | Methods and compositions for the treatment of fluid accumulation in and/ or under the retina | INSERM INST NAT DE LA SANTÉ ET DE LA RECH MÉDICALE (FR) | 2016-01-13 | — | — | EP | disclosed |
| US-20130131024-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID ACCUMULATION IN AND/ OR UNDER THE RETINA | INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE) (FR) | 2013-05-23 | — | — | US | disclosed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | NEKTAR THERAPEUTICS (US) | 2010-11-11 | — | — | US | disclosed |
| WO-2009045539-A2 | OLIGOMER-CORTICOSTEROID CONJUGATES | NEKTAR THERAPEUTICS AL, CORPORATION (US) | 2009-04-09 | — | — | WO | disclosed |
| CN-1320880-C | Improved formulation for topical non-invasive application in vivo | IDEA INNOVAT DERMALE APPL GMBH (DE) | 2007-06-13 | — | — | CN | disclosed |
| CN-1082363-C | Methods of using cyclicpolyanionic polyol derivatives for regulating skin wrinkles | P & G CO (US) | 2002-04-10 | — | — | CN | disclosed |
| CN-1327382-A | Improved formulation for topical non-invasive application in vivo | IDEA INNOVAT DERMALE APPL GMBH (DE) | 2001-12-19 | — | — | CN | disclosed |
| CN-1145584-A | Methods of using cyclicpolyanionic polyol derivatives for regulating skin wrinkles | PROCTER & GAMBLE (US) | 1997-03-19 | — | — | CN | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130131024-A1 | METHODS AND COMPOSITIONS FOR THE TREATMENT OF FLUID ACCUMULATION IN AND/ OR UNDER THE RETINA | AQP3, AQP1, AQP4 | NR3C1 594/4885PGR 1818/4885HIF1A 364/4885 |
| US-20100286107-A1 | Oligomer-Corticosteroid Conjugates | SERPINA6, NR3C2, NR3C1 | NR3C1 3/4885PGR 1161/4885HIF1A 4786/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.